Cefixime Tablets
Ingredients
The main ingredient of this product is cefixime
Molecular formula:
C16H15N5O7S2·3H2O
Molecular weight: 507.50
character
This product is white or almost white film coated tablets. After removing the film coating, it appears white or light yellow.
Usage and dosage
Adults and children weighing more than 30 kg:
Oral, 0.1g twice a day; adult severe infection can be increased to 0.2g twice a day.
Children:
Take it orally. The daily dosage is halved for adults. Or 1.5-3.0 mg / kg, twice a day. Or follow the doctor's advice.
Adverse reactions
In the total 12879 cases, 294 cases (2.58%) of adverse reactions were found, including abnormal clinical examination values. These adverse reactions included 112 cases (0.87%) of gastrointestinal symptoms such as diarrhea, 29 cases (0.23%) of skin symptoms such as rash, and 78 cases (0.61%) of abnormal clinical examination values, 58 cases (0.45%) of increased got, 26 cases (0.20%) of increased eosinophils, etc.
(1) Serious adverse reactions were observed
1. Shock: due to the possibility of causing shock (< 0.1%), close observation should be carried out. In case of discomfort, abnormal feeling in mouth, asthma, dizziness, constipation, tinnitus, sweating, etc., the administration should be stopped and appropriate treatment should be taken;
2. Anaphylactic symptoms: the possibility of anaphylactic symptoms (including dyspnea, systemic flushing, angioneurotic edema, urticaria, etc.) (< 0.1%) should be closely observed. If there is any abnormality, stop the administration and take appropriate measures;
3. Skin lesions: the possibility of skin and mucous membrane eye syndrome (Stevens Johnson syndrome, 0.1%) and toxic epidermal necrosis (Lyell syndrome, 0.1%) should be closely observed. If there are symptoms such as fever, headache, joint pain, skin or mucous erythema, blisters, skin tension, burning sensation and pain, the administration should be stopped and appropriate treatment should be taken;
4. Blood disorders: the possibility of agranulocytosis (< 0.1%, early symptoms: fever, sore throat, headache, burnout, etc.), hemolytic anemia (< 0.1%, early symptoms: fever, hemoglobinuria, anemia, etc.), thrombocytopenia (< 0.1%, early symptoms: punctate hemorrhage, purpura, etc.) and other cephalosporins causing pancytopenia Therefore, close observation, such as regular inspection, should be carried out. In case of any abnormality, drug administration should be stopped and appropriate measures should be taken;
5. Renal dysfunction: due to the possibility of causing severe renal dysfunction (< 0.1%) such as acute renal insufficiency, close observation should be carried out, such as regular examination, etc. in case of abnormality, drug administration should be stopped and appropriate treatment should be taken;
6. Colitis: may cause severe colitis with bloody stool, such as pseudomembranous colitis (< 0.1%). In case of abdominal pain and recurrent diarrhea, the administration should be stopped immediately and appropriate measures should be taken;
7. Interstitial pneumonia, pie syndrome: interstitial pneumonia with fever, cough, dyspnea, chest X-ray abnormalities, eosinophilia and other symptoms, the possibility of pie syndrome (respectively < 0.1%). If the above symptoms occur, the drug should be stopped, and appropriate treatment such as glucocorticoid should be taken;
(2) Other adverse reactions
The incidence of adverse reactions in 0.1-5% is common, and less than 0.1% is rare.
Allergy: common rash, urticaria, erythema, rare pruritus, fever, edema;
Blood: eosinophilia was common (0.1-5%), neutropenia was rare;
Liver: ALT / GPT and AST / got were increased, jaundice was rare;
Kidney: rare increase of urea nitrogen (BUN);
Digestive system: common diarrhea, stomach discomfort, rare nausea, vomiting, abdominal pain, chest burning, loss of appetite, abdominal fullness, constipation;
Dysbacteriosis: stomatitis and oral candidiasis are rare;
Vitamin deficiency: rare vitamin K deficiency (hypothrombin, bleeding tendency, etc.), vitamin B deficiency (glossitis, stomatitis, loss of appetite, neuritis, etc.);
Others: headache, dizziness.
taboo
Allergic to this or other cephalosporins.
matters needing attention
1. In order to prevent the emergence of drug-resistant strains, the sensitivity should be confirmed in principle before using this product, and the dose should be controlled at the minimum dose required for disease control.
2. For patients with severe renal dysfunction, because the drug concentration can be maintained in the blood, it should be reduced according to the renal function, and the interval of administration should be increased.
3. The following patients should be treated with caution:
(1) Patients with a history of allergy to penicillins.
(2) I or parents, brothers, with easy to cause bronchial asthma, rash, urticaria and other allergic symptoms of patients with physical constitution.
(3) Patients with severe renal dysfunction.
(4) Patients with oral administration difficulties or non oral nutrition, and patients with systemic cachexia. The symptoms of vitamin K deficiency should be observed.
4. Due to the possibility of shock, medical history should be fully inquired before administration.
5. Do not mix milk, juice, etc. with medicine.
6. Impact on clinical test results:
(1) In addition to the test paper reaction, we should pay attention to the possibility of false positive in urine sugar test of Benedict reagent, Fehling reagent and clinitest.
(2) We should pay attention to the possibility of direct Coombs test positive.
| Cephalosporin Antibacterial |
Specifications |
| Cefadroxil Capsules |
250mg, 500mg |
| Cefadroxil Tablets |
250mg, 500mg |
| Cefalexin Capsules |
125mg, 250mg, 500mg |
| Cefixime Tablets |
100mg, 200mg, 400mg |
| Cefixime Dispersible Tablets |
100mg, 200mg, 400mg |
| Cefixime Capsules |
100mg, 200mg, 400mg |
| Cefixime Granules |
100mg, 200mg, 400mg |
| Cefuroxime Axetil Tablets |
125mg, 250mg, 500mg |
| Cefradine Capsules |
250mg, 500mg |
| Cefradine Tablets |
250mg, 500mg |
| Cefotiam Hexetil Hydrochloride Tablets |
100mg, 200mg |
Audited Supplier 
){kind=link}